Preventing Protein Instability

Protein-based therapeutics are highly sensitive to physical agitation, particularly during medication preparation and administration. The formation of air bubbles and foam can cause significant structural instability, resulting in protein denaturation and aggregation. These changes threaten the therapeutic efficacy, safety, and consistency of biologics across human and veterinary medicine.

This white paper introduces I2F , a novel device engineered to mechanically eliminate air bubbles during medication handling, thereby reducing agitation-induced stress on protein formulations. Unlike chemical stabilizers or antifoaming agents, I2F provides a non-chemical, workflow-compatible solution that enhances protein stability without altering formulation composition.

Supporting data and case studies demonstrate that I2F:

• Minimizes protein aggregation by eliminating air-liquid interfaces,

• Preserves functional protein integrity during preparation and administration,

• Reduces medication waste,

• Improves cost-efficiency and patient safety.

This paper explores the mechanisms by which agitation disrupts protein structure, highlights the comparative advantages of I2F over traditional stabilizers, and outlines its practical applications across healthcare, biopharmaceuticals, and veterinary medicine. I2F represents a scalable, affordable innovation that addresses a critical need for quality preservation in protein-based therapies.